Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › LGND
RICE HALL JAMES & ASSOCIATES, LLC position in LGND
LIGAND PHARMACEUTICALS INC · Health Care
RICE HALL JAMES & ASSOCIATES, LLC reported holding 223,908 shares of LGND (LIGAND PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$69.9M, representing 3.71% of its reported portfolio and ranking #1 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed LGND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RICE HALL JAMES & ASSOCIATES, LLC's LGND position evolved
RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in LGND in Q3 2023 at 282,961 shares (US$17.0M). The position peaked in Q2 2026 at 270,052 shares, worth US$85.4M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 223,908 shares valued at US$69.9M — a reduction of -46,144 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 282.96K | $16.96M | New |
| Q4 2023 | 276.01K | $19.71M | Reduce |
| Q1 2024 | 279.78K | $20.45M | Add |
| Q2 2024 | 292.48K | $24.64M | Add |
| Q3 2024 | 312.88K | $31.32M | Add |
| Q4 2024 | 304.93K | $32.67M | Reduce |
| Q1 2025 | 297.22K | $31.25M | Reduce |
| Q2 2025 | 337.35K | $38.35M | Add |
| Q3 2025 | 294.49K | $52.17M | Reduce |
| Q4 2025 | 279.63K | $52.87M | Reduce |
| Q1 2026 | 283.57K | $56.61M | Add |
| Q2 2026 | 270.05K | $85.36M | Reduce |
| Q3 2026 | 223.91K | $69.94M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LGND and 13F data
LGND (LIGAND PHARMACEUTICALS INC) is a Health Care company. 48 other funds we track also report a position in LGND — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$205.7M), Chicago Capital, LLC (US$172.2M), Stephens Investment Management Group LLC (US$139.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LGND
- CONGRESS ASSET MANAGEMENT CO 658.56K sh · $205.71M · Q3 2026
- Chicago Capital, LLC 551.23K sh · $172.19M · Q3 2026
- Stephens Investment Management Group LLC 446.14K sh · $139.36M · Q3 2026
- WOLVERINE ASSET MANAGEMENT LLC 50.37M sh · $84.80M · Q3 2026
- GW&K Investment Management, LLC 241.76K sh · $75.52M · Q3 2026
- NEXT CENTURY GROWTH INVESTORS LLC 192.39K sh · $60.10M · Q3 2026
- Ranger Investment Management, L.P. 185.65K sh · $57.99M · Q3 2026
- Private Capital Management, LLC 166.02K sh · $52.48M · Q2 2026
- ASHFORD CAPITAL MANAGEMENT INC 166.34K sh · $51.96M · Q3 2026
- Granahan Investment Management, LLC 154.32K sh · $48.20M · Q3 2026
- SILVERBACK ASSET MANAGEMENT LLC 25.00M sh · $42.00M · Q3 2026
More on RICE HALL JAMES & ASSOCIATES, LLC
FAQ
How long has RICE HALL JAMES & ASSOCIATES, LLC held LGND?
RICE HALL JAMES & ASSOCIATES, LLC has disclosed LGND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RICE HALL JAMES & ASSOCIATES, LLC's current position in LGND?
As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 223.91K shares of LGND (LIGAND PHARMACEUTICALS INC), valued at $69.94M, representing 3.71% of its reported portfolio and ranking #1.
Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling LGND?
In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in LGND. The position peaked in Q2 2026 at 270.05K shares.
Which other funds hold LGND?
Other major institutional holders of LGND include CONGRESS ASSET MANAGEMENT CO, Chicago Capital, LLC, Stephens Investment Management Group LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.